Topic summary

Amylin receptor signalling and satiety

Pharmacology › Receptor biology tirzepatide semaglutide amylin analogues Wiki

This is a generated summary. It shows the 5 most-liked posts from a topic of 27, in their original order, with the accepted answer included where one exists. It is a reading aid and it will miss nuance — the full topic is the record.

t.nardoneTL3Regular19 Oct 2025#3

Community wiki post. Any member at trust level 3 or above can edit this post; every edit is recorded. Last edited by outline_first on 1 Feb 2026.

10 Jan 2026 — coldchain_liu: Replaced an unsourced figure with the published one and cited it.
24 Feb 2026 — r.venkatesan: Removed a claim that the cited source did not support.
1 Feb 2026 — outline_first: Clarified the distinction that was causing repeat questions below.

Editors: coldchain_liu, r.venkatesan, outline_first

GLP-1 receptor agonism produces its metabolic effects through more than one route: central satiety signalling, delayed gastric emptying, and glucose-dependent insulin secretion. Attributing everything to one of them is where most simplified accounts go wrong.

Adding it in case it saves somebody the afternoon it cost me.

18 likes 9mo

n.rowntreeTL3Regular22 Oct 2025#7

Second this, and I would have said it less carefully.

24 likes 9mo

trough_indexTL3Regular28 Oct 2025#16

s.bergstrom, post #11: Building on post #9 rather than restating it. Where a mechanism is proposed to explain an effect, the useful follow-up is what observation would distinguish it from the alternative. Most mechanistic threads here never get asked that. Go to post

Post #13 and I disagree about the size of the effect, not about the direction.

The honest answer on amylin receptor signalling and satiety is that it depends, and the useful part is the list of what it depends on. Four items, in rough order of how much they matter.

Most people get the first two right and then argue about the fourth.

23 likes in reply to #11 9mo

e.verhoevenTL231 Oct 2025#21

KTurkington, post #18: Glucagon receptor agonism raises energy expenditure and promotes hepatic fat oxidation. In a triple agonist the incretin limbs offset the glycaemic consequence, which is why the combination is not self-defeating. Adding a source would improve this post and I do not have one to hand. Go to post

An update on my earlier amylin receptor signalling and satiety post: the pattern held for another six weeks and then stopped, which I did not predict and cannot explain.

19 likes in reply to #18 9mo

a.asanteTL22 Nov 2025#25

r.laurent, post #24: Picking up post #21: that is the part I would want checked first. Glucose dependence is the property that distinguishes incretin-mediated insulin secretion from a sulfonylurea. It is also why hypoglycaemia risk from these compounds alone is low. Go to post

Signalling through cyclic AMP is the canonical pathway and is not the only one. Beta-arrestin recruitment differs between ligands and its clinical significance here is unestablished.

The right answer here may simply be that it has not been measured.

26 likes in reply to #24 9mo

Read the full topic (27 posts)

This topic was referenced in

Biased agonism: a real phenomenon, an over-used explanationPharmacology › Receptor biology · 135 replies

Suggested topics

Topic	Participants	Replies	Views	Activity
GLP-1 receptor distribution: central and peripheral Pharmacology › Receptor biology semaglutide amylin analogues retatrutide long read Posting this under the heading it deserves: GLP-1 receptor distribution: central and peripheral Everything below is what sits behind that. I have spent a fortnight trying to pin GLP-1 receptor distribution…	+90	98	30k	22h
Why appetite effects are mostly central Pharmacology › Receptor biology amylin analogues tirzepatide semaglutide long read Why appetite effects are mostly central I have a specific reason for asking rather than idle curiosity, and the context is below. Appetite effects: what I expected, what I found, and the gap between them. I…		2	56k	16mo
Revisiting: GLP-1 receptor distribution: central and peripheral Pharmacology › Receptor biology amylin analogues tirzepatide retatrutide long read Revisiting: GLP-1 receptor distribution: central and peripheral — setting out what I have, and where I think it stops being reliable. An honest uncertainty about GLP-1 receptor distribution rather than a…	+61	66	15k	8mo
Biased agonism: a real phenomenon, an over-used explanation Pharmacology › Receptor biology semaglutide retatrutide long read tirzepatide Posting this under the heading it deserves: Biased agonism: a real phenomenon, an over-used explanation Everything below is what sits behind that. Trying to work out what would count as evidence on biased…	+130	135	23k	16mo
GIP receptor agonism and the argument about direction — does this still hold? Pharmacology › Receptor biology long read amylin analogues retatrutide Solved GIP receptor agonism and the argument about direction — does this still hold? — that is the question, and I have not found it answered plainly anywhere I have looked. A question about GIP receptor agonism…	+10	14	15k	16h

Related topics — sharing the tags tirzepatide, semaglutide, amylin analogues

Topic	Participants	Replies	Views	Activity
What is genuinely unknown about long-term amylin agonism Compounds › Cagrilintide & amylin analogues randomised trial cagrilintide cagrisema amylin analogues Solved What is genuinely unknown about long-term amylin agonism — that is the question, and I have not found it answered plainly anywhere I have looked. A comparison question rather than a question about one…	+83	91	46k	1d
Half-life, steady state, and accumulation worked through Pharmacology › Pharmacokinetics semaglutide liraglutide tirzepatide Wiki Half-life, steady state, and accumulation worked through Writing it up because I had to work it out twice and would rather nobody else did. Working through the kinetics rather than the pharmacology, because I…	+115	130	44k	13mo
SURPASS-2 and the comparator dose question that will not go away Compounds › Tirzepatide SURPASS programme randomised trial effect size SURMOUNT programme SURPASS-2 and the comparator dose question that will not go away — setting out what I have, and where I think it stops being reliable. A methods question rather than a substantive one, about SURPASS-2.…	+101	111	1.5k	18mo
Cagrilintide's dosing interval and the pharmacokinetics behind it Compounds › Cagrilintide & amylin analogues effect size randomised trial amylin analogues cagrisema Solved Cagrilintide's dosing interval and the pharmacokinetics behind it — setting out what I have, and where I think it stops being reliable. Putting the numbers in the first post, because a question about a…	+98	105	24k	10mo
Peak-to-trough ratio at steady state for a weekly agent — the long version Pharmacology › Pharmacokinetics semaglutide missed dose tirzepatide worked example Under review Peak-to-trough ratio at steady state for a weekly agent — the long version Writing it up because I had to work it out twice and would rather nobody else did. A narrow question about Peak-to-trough ratio,…	+57	61	708	1d